StreetInsider.com News Articles

OSR Holdings advances biotech licensing deal worth up to $815 million

Mon, 02 Feb 2026 09:57:30 -0500

OSR Holdings Inc. (NASDAQ: OSRH) provided an update on its strategic initiatives, including progress on a licensing transaction for its biotech subsidiary's lead asset and potential merger discussions between two medical device units.

The company's Swiss biotech subsidiary, Vaximm AG, continues working toward finalizing a global licensing transaction for VXM01 with BCM Europe AG. The deal structure includes up to $815 million in development, regulatory and commercial milestones, plus $30 million in upfront consideration split between $15 million in cash and $15 million in digital assets.

OSR Holdings is also pursuing a potential merger between its medical device subsidiaries RMC and Woori

OSR Holdings advances biotech licensing deal worth up to $815 million

Mon, 02 Feb 2026 09:57:30 -0500

OSR Holdings is also pursuing a potential merger between its medical device subsidiaries RMC and Woori

CEO Statement to Shareholders

Mon, 02 Feb 2026 09:50:00 -0500

BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation

As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.

I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings, Inc. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones.

Progress

CEO Statement to Shareholders

Mon, 02 Feb 2026 09:50:00 -0500

BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation
As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.
I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings, Inc. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones.
Progress

Form 8-K OSR Holdings, Inc. For: Jan 26

Tue, 27 Jan 2026 09:27:00 -0500
si-local-file:///var/storage/secattach/20260127/25897554.html

Form 8-K OSR Holdings, Inc. For: Jan 26

Tue, 27 Jan 2026 09:27:00 -0500
si-local-file:///var/storage/secattach/20260127/25897554.html

OSR Holdings completes Woori IO acquisition, reviews device unit merger

Tue, 27 Jan 2026 08:32:50 -0500

OSR Holdings Inc. (NASDAQ: OSRH) completed its acquisition of Woori IO on January 26, making the South Korean medical device company a consolidated subsidiary, according to a company statement.
The transaction adds Woori IO's noninvasive glucose monitoring and wearable health technologies to OSR Holdings' medical device portfolio. Woori IO develops biosensing technologies using near-infrared spectroscopy for glucose tracking in wearable devices.
Historical Woori IO shareholders agreed to a three-year equity alignment framework, exchanging their interests in OSR Holdings Co. Ltd. for NASDAQ-listed common stock only at a reference price of $10 per share. The company said this structure aims to prevent near-term

OSR Holdings completes Woori IO acquisition, reviews device unit merger

Tue, 27 Jan 2026 08:32:50 -0500

OSR Holdings Inc. (NASDAQ: OSRH) completed its acquisition of Woori IO on January 26, making the South Korean medical device company a consolidated subsidiary, according to a company statement.
The transaction adds Woori IO's noninvasive glucose monitoring and wearable health technologies to OSR Holdings' medical device portfolio. Woori IO develops biosensing technologies using near-infrared spectroscopy for glucose tracking in wearable devices.
Historical Woori IO shareholders agreed to a three-year equity alignment framework, exchanging their interests in OSR Holdings Co. Ltd. for NASDAQ-listed common stock only at a reference price of $10 per share. The company said this structure aims to prevent near-term

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Tue, 27 Jan 2026 08:30:00 -0500

BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries.
Woori IO Acquisition Closed
OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026. As a result, Woori IO is now a consolidated subsidiary of OSRH,

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Tue, 27 Jan 2026 08:30:00 -0500

BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries.
Woori IO Acquisition Closed
OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026. As a result, Woori IO is now a consolidated subsidiary of OSRH,

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Thu, 22 Jan 2026 09:55:00 -0500

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Vaximm names Sébastien Wieckowski as chief scientific officer

Fri, 16 Jan 2026 09:24:26 -0500

Vaximm AG, a subsidiary of OSR Holdings Inc. (NASDAQ: OSRH), appointed Sébastien Wieckowski as chief scientific officer, the company announced January 16.
Wieckowski has worked with Vaximm since 2016 and brings experience in immunology and data science. The Swiss-German biotechnology company focuses on oral T-cell immunotherapies for cancer treatment.
"Having worked closely with him since 2016, I have witnessed firsthand his deep scientific and technical mastery of our oral vector technology," said Andreas Niethammer, Vaximm's chief executive officer.
The appointment occurs as Vaximm advances its lead candidate VXM01 through clinical development stages. The company uses live, attenuated bacterial vectors to deliver tumor-associated antigens

Vaximm names Sébastien Wieckowski as chief scientific officer

Fri, 16 Jan 2026 09:24:26 -0500

Vaximm AG, a subsidiary of OSR Holdings Inc. (NASDAQ: OSRH), appointed Sébastien Wieckowski as chief scientific officer, the company announced January 16.
Wieckowski has worked with Vaximm since 2016 and brings experience in immunology and data science. The Swiss-German biotechnology company focuses on oral T-cell immunotherapies for cancer treatment.
"Having worked closely with him since 2016, I have witnessed firsthand his deep scientific and technical mastery of our oral vector technology," said Andreas Niethammer, Vaximm's chief executive officer.
The appointment occurs as Vaximm advances its lead candidate VXM01 through clinical development stages. The company uses live, attenuated bacterial vectors to deliver tumor-associated antigens

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Fri, 16 Jan 2026 09:20:00 -0500

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Fri, 16 Jan 2026 09:20:00 -0500

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Fri, 16 Jan 2026 09:20:00 -0500

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Fri, 16 Jan 2026 09:20:00 -0500

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Fri, 16 Jan 2026 09:20:00 -0500

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.